1OP 2198Alternative Names: 1OP-2198
Latest Information Update: 08 Nov 2016
At a glance
- Originator 1st Order Pharmaceuticals
- Class Small molecules
- Mechanism of Action KCNQ potassium channel agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders
Most Recent Events
- 28 Oct 2016 Preclinical trials in Neurological disorders in USA (unspecified route) (1st Order Pharmaceuticals website, October 2016)